<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310957</url>
  </required_header>
  <id_info>
    <org_study_id>SGNLVA-002</org_study_id>
    <secondary_id>KEYNOTE 721</secondary_id>
    <secondary_id>2017-002289-35</secondary_id>
    <nct_id>NCT03310957</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer</brief_title>
  <official_title>Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with&#xD;
      triple-negative breast cancer. It will find out what side effects happen when participants&#xD;
      get these two drugs. A side effect is anything the drugs do besides treating cancer.&#xD;
      Pembrolizumab is a drug that can be used to treat triple-negative breast cancer. The trial&#xD;
      will also find out if the drugs work to treat this type of cancer. Participants in this study&#xD;
      have metastatic breast cancer. This means the cancer has spread to other parts of the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this study is to evaluate the combination of LV, which targets LIV-1-&#xD;
      expressing tumor cells, with the checkpoint inhibitor pembrolizumab for patients with&#xD;
      unresectable locally-advanced or metastatic triple-negative breast cancer. These two drugs&#xD;
      act through distinct and possibly complementary modes of action.&#xD;
&#xD;
      This is a single-arm, open-label, multicenter trial. Patients given LV and pembrolizumab&#xD;
      during dose escalation will be monitored for frequency of dose-limiting toxicities to&#xD;
      determine a recommended doses for expansion cohorts. In addition to safety measures,&#xD;
      objective response rate, progression-free survival, overall survival, and other efficacy&#xD;
      outcomes will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate</measure>
    <time_frame>Up to 18 weeks following last dose; approximately 1 year</time_frame>
    <description>Confirmed ORR as determined by investigator according to RECIST v 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose; approximately 10 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose; approximately 10 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities</measure>
    <time_frame>Through 1 month following last dose; approximately 10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>DOR as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>Proportion of patients with complete response (CR), partial response (PR), or stable disease (SD) as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>PFS as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>OS is defined as the time from start of study treatment to date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">161</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>LV plus pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LV + pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ladiratuzumab vedotin</intervention_name>
    <description>Into the vein (IV; intravenously)</description>
    <arm_group_label>LV plus pembrolizumab</arm_group_label>
    <other_name>LV</other_name>
    <other_name>SGN-LIV1A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion every 3 weeks</description>
    <arm_group_label>LV plus pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic or locally-advanced, histologically documented TNBC (absence of HER2, ER,&#xD;
             and PR expression)&#xD;
&#xD;
          -  Have not previously received cytotoxic therapy for the treatment of unresectable&#xD;
             locally-advanced breast cancer or metastatic breast cancer&#xD;
&#xD;
          -  At least 6 months since prior treatment with curative intent and recurrence&#xD;
&#xD;
          -  At least 1 tumor 10mm in diameter or greater OR lymph node of at least 15 mm in short&#xD;
             axis&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Able to provide biopsy tissue for biomarker analysis&#xD;
&#xD;
          -  Meet baseline laboratory data criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior immune-oncology therapy&#xD;
&#xD;
          -  Pre-existing neuropathy of at least Grade 2&#xD;
&#xD;
          -  History of carcinomatous meningitis or active central nervous system (CNS) metastases.&#xD;
             Patients are eligible if CNS metastases are adequately treated and patients have&#xD;
             neurologically returned to baseline (except for residual signs or symptoms related to&#xD;
             the CNS treatment) for at least 4 weeks prior to enrollment. Patients must be off&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Received prior radiotherapy within 2 weeks of start of study treatment or have not&#xD;
             adequately recovered from prior radiotherapy&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment within the past 2 years&#xD;
&#xD;
          -  History of interstitial lung disease&#xD;
&#xD;
          -  Current pneumonitis or history of pneumonitis requiring steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zejing Wang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuzhat Siddiqui</last_name>
      <phone>205-934-7167</phone>
      <email>nuzhat@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Erica M Stringer-Reasor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Ahorro</last_name>
      <phone>310-423-1047</phone>
      <email>AlyssaFrancesc.Ahorro@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Anna Rosen</last_name>
      <phone>310-423-8030</phone>
      <email>Anna.Rosen@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Reva K Basho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Parajuli</last_name>
      <phone>714-456-8614</phone>
      <email>rparajul@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Ritesh Parajuli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Irvine - Newport</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Dich</last_name>
      <phone>714-456-8614</phone>
      <email>mdich@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Ritesh Parajuli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossen Roussev</last_name>
      <phone>303-385-2000</phone>
      <email>rossen.roussev@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenny Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Whittingham Cancer Center / Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah G Evans</last_name>
      <phone>203-852-2996</phone>
      <email>sarah.evans@wchn.org</email>
    </contact>
    <investigator>
      <last_name>Linda Vahdat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center / Christiana Care Health Systems</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise DeMaio</last_name>
      <phone>302-623-4500</phone>
      <email>denise.a.demaio@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Michael J Guarino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Acker</last_name>
      <phone>407-303-4471</phone>
      <email>ingrid.acker@adventhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Sara Guyler</last_name>
      <phone>407-303-2024</phone>
      <email>sara.guyler@adventhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Alemany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Goodridge</last_name>
      <phone>813-745-1807</phone>
      <email>Dawn.Goodridge@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hyo Heather Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olabusola Awoyemi</last_name>
      <phone>678-298-3242</phone>
      <email>oawoyemi@piedmontcancerinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Rajni Sinha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Falero</last_name>
      <phone>404-778-1900</phone>
      <email>vanessa.falero@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jane L Meisel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ingalls Cancer Care / Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Gravitt</last_name>
      <phone>708-339-4800</phone>
      <email>mmarriott@ingalls.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Gravitt</last_name>
      <phone>708-339-4800</phone>
      <email>lgravitt@ingalls.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kimberly R Kruczek</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danielle Sterrenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivy Abraham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center / Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Bartolotta</last_name>
      <phone>708-327-3148</phone>
      <email>mbartolotta@luc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gaye Moran</last_name>
      <phone>708-327-3229</phone>
      <email>gwmoran@luc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathy Albain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha Khalil</last_name>
      <phone>410-328-2703</phone>
      <email>ntait@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maha Khalil</last_name>
      <phone>410-328-2703</phone>
      <email>maha.khalil@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine H. R. HR Tkaczuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori A Green</last_name>
      <phone>612-863-1093</phone>
      <email>jacquelyn.underhill@allina.com</email>
    </contact>
    <contact_backup>
      <last_name>Lori Green</last_name>
      <phone>612-863-1093</phone>
      <email>lori.green@allina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michaela Tsai</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Krie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen T Hutton</last_name>
      <phone>855-663-7524</phone>
      <email>clittrel@saint-lukes.org</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Murray</last_name>
      <phone>855-663-7524</phone>
      <email>cwmurray@saint-lukes.org</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy J Pluard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-436-1755</phone>
      <email>mmackenzie@smgnj.com</email>
    </contact>
    <investigator>
      <last_name>Steven W Papish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karwyn S Gustafson, MD</last_name>
      <phone>505-272-4946</phone>
      <email>ksgustafson@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Ursa Brown-Glaberman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Andreopoulou</last_name>
      <phone>646-962-2064</phone>
      <email>ela9082@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Eleni Andreopoulou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Lopez</last_name>
      <phone>214-370-1846</phone>
      <email>rita.lopez2@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Sulema Silva</last_name>
      <phone>214-370-1000</phone>
      <email>sulema.silva@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joyce O'Shaughnessy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Houston Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Fru</last_name>
      <phone>713-467-1722</phone>
      <email>nina.fru@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Hina Nazir</last_name>
      <phone>713-467-1722</phone>
      <email>hina.nazir@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michelina Cairo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Wilson</last_name>
      <phone>210-224-3820</phone>
      <email>kathryn.wilson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sharon Wilks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Hazen</last_name>
      <email>SEH3AA@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Dillon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Indira Dastan</last_name>
    </contact>
    <investigator>
      <last_name>Jennifer M Specht</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaveta Vinayak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynakologisches Zentrum Bonn Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <state>Other</state>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christian Kurbacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Bottrop</name>
      <address>
        <city>Bottrop</city>
        <state>Other</state>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Hans Christian Kolberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <state>Other</state>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Hermann Voss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Other</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Peter Fasching</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte - Evang. Huyssens-Stiftung</name>
      <address>
        <city>Essen</city>
        <state>Other</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Sherko Kummel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Munchen</name>
      <address>
        <city>Munchen</city>
        <state>Other</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Rachel Wuerstlein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum Munich</name>
      <address>
        <city>Munich</city>
        <state>Other</state>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar der Technischen Universitat Munchen</name>
      <address>
        <city>Munich</city>
        <state>Other</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Johannes Ettl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Other</state>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Young jin Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam</city>
        <state>Other</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Yong Wha Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>01802</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Woo-Chul Noh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min-Ki Seong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Seock-Ah Im</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Joo Hyuk Sohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Young-Hyuck Im</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Joan Albanell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Mafalda Oliveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala D'Oncologia Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Villanueva Vazquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Jaen</city>
        <state>Other</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Pedro Sanchez Rovira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario La Coruna</name>
      <address>
        <city>La Coruna</city>
        <state>Other</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Silvia Antolin Novoa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico MD Anderson</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Laura Garcia Estevez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Javier Cortes Castan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Luis Manso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HM Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seagen Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Valentina Boni</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emiliano Calvo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Breast carcinoma</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Locally-advanced breast cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Tumors, breast</keyword>
  <keyword>Breast tumors</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>LIV-1 protein, human</keyword>
  <keyword>Ladiratuzumab vedotin</keyword>
  <keyword>hLIV22-vcMMAE</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

